ѻý

Morning Break: Man With 3 Faces; FDA Stays Busy; Azar's Diverticulitis

<ѻý class="mpt-content-deck">— Health news and commentary from around the Web gathered by the ѻý staff
Last Updated April 19, 2018
MedpageToday

Note that some links may require subscriptions.

Called the "man with three faces," a patient in France gets -- a first in medicine -- after medication that interfered with his anti-rejection treatment left his face with no eyelids, ears or skin. (CBS News)

In other second chances: a week after a ", fostamatinib (Tavalisse) was yesterday, says Rigel Pharmaceuticals, for second-line treatment of chronic immune thrombocytopenia in adults. (BioSpace)

for treatment of X-linked hypophosphatemia, a rare, inherited form of rickets that doesn't respond well to vitamin D.

HHS says Secretary Alex Azar for treatment of diverticulitis. (Washington Times)

Not quite there yet, but data on Epidiolex -- a cannabidiol therapy for Lennox-Gastaut and Dravet syndrome epilepsy -- "appears to support approval," according to ahead of an advisory committee vote later this week, according to FierceBiotech. Check ѻý later for more details.

Federal appeals court halts " to combat high drug costs. (Kaiser Health News)

Mayo Clinic researchers find no evidence that end up with lower intelligence. (Anesthesiology)

FDA warns of .

New CDC Director Robert Redfield had to step down from four groups -- including a biotech company and a faith-based AIDS organization -- and sold off stocks to at his new post. (Wall Street Journal)

to The New York Times' in-depth article on withdrawal from antidepressants.

Mouse-dropping analysis finds that a quarter of . (TIME)

And in more NYC news, the city said it will , who conducted "non-consensual medical experimentation" on black women.

Morning Break is a daily guide to what's new and interesting on the Web for healthcare professionals, powered by the ѻý community. Got a tip? Send it to us: MPT_editorial@everydayhealthinc.com.